BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium
October 29, 2021 15:44 ET | BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Oct. 29, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory, and degenerative diseases...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Researchers Discover Previously Unknown Role of BioAegis’ Therapeutic Gelsolin as Key Signaling Protein Vital for Regulating Immune Cell Inflammatory Response
September 28, 2021 11:17 ET | BioAegis Therapeutics
This biological phenomenon, quorum sensing in macrophages, regulates the transition of cells from inflammatory to healing phenotype. NORTH BRUNSWICK, New Jersey, Sept. 28, 2021 (GLOBE NEWSWIRE) --...
Olives and Wine: Conagen Makes Accessible Antioxidant Hydroxytyrosol by Fermentation
September 10, 2021 15:25 ET | Conagen
Bedford, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Leveraging its robust phenolics platform, Conagen announced the expansion of the health ingredient portfolio of its commercial partner Blue...
22157.jpg
Global Immunity Boosting Foods Market Report 2021 with Analysis of COVID-19 Effects on Consumers
August 31, 2021 04:43 ET | Research and Markets
Dublin, Aug. 31, 2021 (GLOBE NEWSWIRE) -- The "Immunity Boosting Foods: Gut Health & General Immunity Improvement" report has been added to ResearchAndMarkets.com's offering. Immunity Boosting...
Blue California Opens New Possibilities in Functional Food and Beverages Following Dihydroquercetin (DHQ) GRAS Status
May 25, 2021 05:39 ET | Blue California Ingredients
Rancho Santa Margarita, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Blue California’s Taxifolin BC-DHQ® with super antioxidant and anti-inflammatory properties is now Generally Recognized As Safe...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
Study Identifies New Role of BioAegis’ ‘Inflammation Regulator’ Gelsolin Relevant for a Range of Inflammatory Diseases
April 08, 2021 18:58 ET | BioAegis Therapeutics
Gelsolin mitigates vascular damage by preventing release of IL-1β microparticles after trauma of high pressure and decompression.  Gelsolin is non-immunosuppressive unlike current treatments to quell...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
NIH and Other Independent Studies Confirm Low Levels of BioAegis’ ‘Inflammation Regulator Protein,’ Gelsolin, Associated with COVID-19 Severity
February 02, 2021 14:05 ET | BioAegis Therapeutics
MORRISTOWN, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
Add Kyolic Aged Garlic Extract for Better Heart Health
December 03, 2020 12:26 ET | Wakunaga of America: Kyolic Aged Garlic Extract
MISSION VIEJO, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- The past year has been a demanding one on the heart in more ways than one, from the stresses of social distancing with loved ones and...
22157.jpg
India Immunity Boosting Packaged Products Market Report 2020 with COVID-19 Impact Analysis
November 24, 2020 04:43 ET | Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "India Immunity Boosting Packaged Products Market, by Product Category (Supplements, Beverages, Food and Others), by Distribution Channel (Convenience...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Expands Phase 2 COVID-19 Treatment Clinical Trial in EU for Inflammation Regulator
November 15, 2020 19:35 ET | BioAegis Therapeutics
No drug-related safety signals identified by the independent Data and Safety Monitoring Board.MORRISTOWN, N.J., Nov. 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage,...